My ePortfolio Register   

Radium 223 in the ALSYMPCA trial

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 21.10.11
Views: 3543

Dr Chris Parker – Royal Marsden Cancer Centre, London, UK

Dr Chris Parker talks to ecancer managing editor Prof Gordon McVie at the European Multidisciplinary Cancer Conference in Stockholm about the pivotal ALSYMPCA, phase 3 trial.

The trial deals with radium 223, which is used to treat for bone metastasis in men with metastatic prostate cancer by emitting alpha particles that are highly damaging at only a short range. The trial hopes to show that the short range of radium 223 will destroy the cancer cells but not affect the bone marrow.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence